Genprex Investor Presentation Deck
November 2024, 58 slides
  1. Genprex
  2. Related Decks
  3. Investor Presentation Decks
pioneering gene therapies for patients in need we a i a a | Genprex
forward looking statements | Genprex
our mission | Genprex
program highlights | Genprex
research and development pipeline | Genprex
oncology a | Genprex
why | Genprex
tumor suppressor genes deleted during cancer development | Genprex
delivery system | Genprex
our cancer treatment approach tumor suppressor genes are deleted early during cancer development our method of treating cancer is to reintroduce tumor suppressor genes to patients | Genprex
novel platform to treat cancer | Genprex
targets cancer at its core | Genprex
reduces glycolysis in cancer cells | Genprex
lung cancer by the numbers | Genprex
| Genprex
selective uptake of | Genprex
phase trial | Genprex
| Genprex
reduce tumor growth in resistant tumors | Genprex
| Genprex
phase dose in relapsed patients | Genprex
in small cell lung cancer | Genprex
express low levels of protein | Genprex
approval trial | Genprex
maintenance therapy | Genprex
adds significantly to treatment | Genprex
increased immune response with and | Genprex
| Genprex
induces anti tumor activity in on met vain | Genprex
combined and expression in | Genprex
diabetes a | Genprex
diabetes by the numbers | Genprex
diabetes can cause serious complications in there was approximately death every seconds caused by diabetes | Genprex
diabetes causes serious complications | Genprex
diabetic patients are in need of advanced therapy | Genprex
novel gene therapy diabetes program intends to address both and | Genprex
replenishes levels of insulin tes | Genprex
reversed drug induced diabetes in toxin induced mouse model | Genprex
restored blood glucose in in mouse model for four months | Genprex
induced generation of functional insulin expressing cells from alpha cells in human islets | Genprex
non human primate model of reduced insulin requirements boo a hull lull i | Genprex
decreased insulin requirements and improved glucose tolerance in | Genprex
three month glucose tolerance test eon | Genprex
eight weeks after gene therapy | Genprex
corporate a | Genprex
our team company management | Genprex
our team scientific advisory board | Genprex
our team clinical advisory board | Genprex
our team board of directors | Genprex
achievements upcoming milestones | Genprex
we believe in a future of patient care | Genprex
| Genprex
research references | Genprex
research references | Genprex
appendix | Genprex
significantly reduced tumor growth | Genprex
may enhance first line standard of care | Genprex
| Genprex
See More
Genprex
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Cancer
Lung
Diabetes
Tumor
Delivery
Recent decks by Genprex
Investor Presentation
October 2022
Investor Presentation
October 2022
See all presentations by Genprex (3 decks)
Related decks
Mink Therapeutics
Investor Day
November 2022
Genetron
Results
June 2022
MAIA Biotechnology
Investor Presentation
January 2024
Genelux
Investor Presentation
December 2023
Poseida Therapeutics
IPO
July 2020
Genelux
Investor Presentation
October 2023
BioAtla
Investor Presentation
January 2024
RenovoRx
IPO
August 2021
Recent decks by Genprex
See all presentations (3 decks)
Investor Presentation
October 2022
Investor Presentation
October 2022
Mink Therapeutics
Investor Day
November 2022
Genetron
Results
June 2022
MAIA Biotechnology
Investor Presentation
January 2024
Genelux
Investor Presentation
December 2023
Poseida Therapeutics
IPO
July 2020
Genelux
Investor Presentation
October 2023
BioAtla
Investor Presentation
January 2024
RenovoRx
IPO
August 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights